Activating Transcription Factor 1 is a Prognostic Marker of Colorectal Cancer |
Huang, Guo-Liang
(Sino-American Cancer Research Institute, Guangdong Medical College)
Guo, Hong-Qiang (The Affiliated Cancer Hospital of Zhengzhou University) Yang, Feng (Department of Pharmacy and Life Science, University of South China) Liu, Ou-Fei (The Affiliated Cancer Hospital of Zhengzhou University) Li, Bin-Bin (Sino-American Cancer Research Institute, Guangdong Medical College) Liu, Xing-Yan (Sino-American Cancer Research Institute, Guangdong Medical College) Lu, Yan (Sino-American Cancer Research Institute, Guangdong Medical College) He, Zhi-Wei (Sino-American Cancer Research Institute, Guangdong Medical College) |
1 | Bosilevac JM, Olsen RJ, Bridge JA, Hinrichs SH (1999). Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. J Biol Chem, 274, 34811-8. DOI |
2 | Eferl R, Wagner EF (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer, 3, 859-68. DOI |
3 | Feuerstein ND, Huang S, Hinrichs H, et al (1995). Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J Immunol, 154, 68-79. |
4 | Ghoneim C, Soula-Rothhut M, Blanchevoye C, et al (2007). Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem, 282, 15490-7. DOI |
5 | Gunderson LL, Jessup JM, Sargent DJ, et al (2010). Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol, 28, 264-71. DOI |
6 | Hai T, Hartman MG (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene, 273, 1-11. DOI |
7 | Hsueh YP, Lai MZ (1995). Overexpression of activation transcriptional factor 1 in lymphomas and in activated lymphocytes. J Immunol, 154, 5675-83. |
8 | Huang D, Shipman-Appasamy PM, Orten DJ, et al (1994). Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes. Mol Cell Biol, 14, 4233-43. DOI |
9 | Jean D, Tellez C, Huang S, et al (2000). Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 19, 2721- 30. DOI |
10 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
11 | Kelly D, Kim SJ, Rizzino A (1998). Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells. J Biol Chem, 273, 21115-24. DOI |
12 | Kelly D, Scholtz B, Orten DJ, et al (1995). Regulation of the transforming growth factor-beta 2 gene promoter in embryonal carcinoma cells and their differentiated cells: differential utilization of transcription factors. Mol Reprod Dev, 40, 135-45. DOI |
13 | Lopez-Bergam P, Lau E, Ronai Z (2010). Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer, 10, 65-76. DOI |
14 | Maekawa T, Sano Y, Shinagawa T, et al (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene, 27, 1045-54. DOI |
15 | Okuyama Y, Sowa Y, Fujita T, et al (1996). ATF site of human RB gene promoter is a responsive element of myogenic differentiation. FEBS Lett, 397, 219-24. DOI |
16 | Papassava P, Gorgoulis VG, Papaevangeliou D, et al (2004). Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res, 64, 8573-84. DOI |
17 | Ronai Z, Yang YM, Fuchs SY, et al (1998). ATF2 confers radiation resistance to human melanoma cells. Oncogene, 16, 523-31. DOI |
18 | Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. DOI ScienceOn |
19 | Bhoumik A, Fichtman B, Derossi C, et al (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A, 105, 1674-9. DOI |
20 | Belkhiri A, Dar AA, Zaika A, et al (2008). t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Aktdependent mechanism. Cancer Res, 68, 395-403. DOI |
21 | Bhoumik A, Jones N, Ronai Z (2004). Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A, 101, 4222-7. DOI |
22 | Zucman J, Delattre O, Desmaze C, et al (1993). EWS and ATF-1 gene fusion induced by t (12;22) translocation in malignant melanoma of soft parts. Nat Genet, 4, 341-5. DOI ScienceOn |
23 | Su B, Tang HL, Deng M, et al (2011). Stage-associated dynamic activity profile of transcription factors in nasopharyngeal carcinoma progression based on protein/DNA array analysis. Omics, 15, 49-60. DOI |
24 | Zheng D, Cho YY, Lau AT, et al (2008). Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res, 68, 7650-60. DOI |
![]() |